GE HealthCare Technologies Inc. reported a 3% increase in revenues, reaching $4.8 billion for the first quarter of 2025, with organic revenue growth at 4%. The company's net income attributable to GE HealthCare rose to $564 million, up from $374 million in the previous year, resulting in a net income margin of 11.8%, compared to 8.0% from the prior year. Adjusted earnings before interest and taxes $(EBIT)$ was reported at $715 million, an increase from $681 million, with an adjusted EBIT margin of 15.0%, up from 14.7%. Diluted earnings per share $(EPS)$ improved to $1.23 from $0.81 the previous year, while adjusted EPS increased to $1.01 from $0.90. The company noted strong order growth, with organic orders increasing by a record 10% year-over-year, and a total company book-to-bill ratio of 1.09 times. GE HealthCare's cash flow from operating activities was $250 million, down from $419 million, with free cash flow at $98 million compared to $274 million the previous year. Additionally, the Board of Directors authorized a $1 billion share repurchase program as part of the company's strategic financial initiatives.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。